Immunomedics

Immunomedics is a biopharmaceutical company that specializes in developing monoclonal antibody-based products for the treatment of cancer and other serious diseases. Its corporate objective is to become a fully-integrated biopharmaceutical company. The company was founded in 1982 and headquartered in Morris Plains, New Jersey.

Sacituzumab Govitecan Achieves a 29 Percent Objective Response Rate in 35 Patients With Advanced Urothelial Cancer Who Failed Prior Platinum-Based Regimens and Immunotherapy

Immunomedics Provides Corporate Update

Amgen

Zymeworks Inc

Doctors, researchers, and pharmaceutical experts will converge upon Barcelona to share the latest results in cancer research. Here is a run-down on three to watch.

Cancer Results to Watch at This Weekend’s European Society of Medical Oncology Congress

Immunomedics (IMMU) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session

Immunomedics (IMMU) reported earnings 30 days ago. What's next for the stock?

Why Is Immunomedics (IMMU) Down 13.1% Since Last Earnings Report?

MORRIS PLAINS, N.J., Sept.  04, 2019  (GLOBE NEWSWIRE) --  Immunomedics, Inc. , (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that its TROPHY-U-01 late-breaking abstract on interim results of sacituzumab govitecan in patients with metastatic urothelial cancer (mUC) has been selected for oral presentation at the ESMO 2019 Annual Congress, taking place from  September 27 to October 1, 2019, at the Fira Barcelona, Spain.

Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress

MORRIS PLAINS, N.J., Aug.  28, 2019  (GLOBE NEWSWIRE) --   Immunomedics, Inc.   (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate in fireside chats at the following healthcare conferences:

Immunomedics to Participate  in Upcoming Healthcare Conferences

Immunomedics (IMMU) posts wider-than-expected loss and generates no revenues in the second quarter of 2019.

Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2

Immunomedics, Inc. (IMMU) on Q2 2019 Results - Earnings Call Transcript

Immunomedics stock has risen approximately 8% in the last week since we picked it up in our premium research service. The stock is a good contrarian pick.

Immunomedics: Contrarian Oncology Pick

AbbVie

Medicines

MGM Resorts

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Notable Insider Buys This Past Week: AbbVie, MGM and More

American Airlines

Teva Pharmaceutical

Insider buying can be an encouraging signal for potential investors. Board chairs at pharmaceutical companies made notable buys this week.

Notable Insider Buys This Past Week

Immunomedics, Inc. (IMMU) Management on Q1 2019 Results - Earnings Call Transcript

News for Immunomedics Stock (IMMU)